JNJ / J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can imp more_horizontal

Shares of Johnson & Johnson NYSE: JNJ slid 4.84% lower the week ending October 27, as the company's subsidiary LTL Management is facing a raft of laws more_horizontal

These two market leaders offer you solid earnings prospects and the promise of dividend growth. They both look cheap today, considering their track re more_horizontal

Johnson & Johnson has begun providing documents and information in response to a civil investigation by the U.S. Department of Justice related to free more_horizontal

Johnson & Johnson (NYSE: JNJ) reported its Q3 results last week, with revenues and earnings beating the street estimates. more_horizontal

The Oracle of Omaha favors solid companies that are undervalued -- and he holds on for the long term. Buffett often invests in companies selling goods more_horizontal

This week, two additional companies have been added to The Dividend Income Accelerator Portfolio. Both companies pay an attractive Dividend Yield, hav more_horizontal

Johnson & Johnson has a stable business and one of the most impressive dividend streaks. Visa is one of the two undisputed leaders in an industry that more_horizontal